 Medscape | Cost Restricts RA Drug Access in Europe Medscape The bDMARDs surveyed included infliximab, etanercept, adalimumab, certolizumab pegol, golimumab, abatacept, tocilizumab, and rituximab. The cost of annual treatment with sDMARDs never exceeded GDP, but cost for 1 year of bDMARD treatment ... |
